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Abstract
Background: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection.
We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a
methadone treatment program (MTP).
Methods: Longitudinal study of patients enrolled in a MTP from 1992 to 2010. Socio-demographic and drug use
characteristics, and markers of viral infections were assessed at entry. Vital status was ascertained by clinical charts
and the mortality register. Four calendar periods were defined according to the introduction of preventive and
treatment interventions in Spain. Predictors of death were analyzed by Cox regression models.
Results: 1,678 patients (82.8% men) were included; age at first heroin use was 18.6 years (IQR: 16–23 years), and
age at first entry into a MTP was 30.7 years (IQR: 26–36 years). A total of 441 (26.3%) deaths occurred during 15,124
person-years (p-y) of follow-up (median: 9.2 years, IQR: 4–13 years). HIV infection was the main predictor of death
in men (HR = 3.5, 95% CI: 2.1-5.7) and women (HR = 3.2, 95% CI: 1.2-8.7 ) and main cause of death was HIV/AIDS.
Overall mortality rate was 2.9 per 100 p-y (95% CI: 2.7-3.2 per 100 p-y) and death rates decreased over time: 7.4
per 100 p-y (95% CI: 6.3-8.8 per 100 p-y) for the 1992–1996 period to 1.9 per 100 p-y (95% CI: 1.6-2.4 per 100 p-y)
for the 2007–2010 period. In women, a slightly increase in mortality was observed in recent periods specifically
among HIV-positive women (3.7 per 100 p-y in period 2002–2006 and 4.5 per 100 p-y in 2007–2010).
Conclusions: Significant reductions in mortality of patients in MTP are observed after nineteen years of observation.
However, HIV infection shows a great impact on survival, particularly among HIV-infected women.
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Background
It has been estimated that 1.35 million people are heroin
users in European countries [1]. Heroin dependence is a
chronic disease characterized by compulsive drug-taking
behavior despite serious negative consequences and,
specifically, injection drug users (IDUs) have high prevalence
of severe co-morbidities including blood-borne infectious
diseases, drug overdose, and psychiatric disorders [2-4].
The efficacy of detoxification as the main treatment
intervention is limited, as compared to other therapeutic
options such as opioid substitution therapy (OST) [5].
OST reduces heroin consumption by acting as opioid
receptor agonists on the central nervous system. A
reduction in heroin use further increases adherence to
substitution therapies and facilitates the implementation of
harm-reduction interventions aimed to improve quality of
life and health [5-9]. Such health and social interventions
while in substitution therapy are common for Methadone
Treatment Programs (MTP). MTPs have been used since
the mid-1960 in the United States (U.S.) [10] and more
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recently in Western Europe. Over 20 years of scientific
evidence has demonstrated the effectiveness of OST on
reducing the impact of illegal opiate usage in society
[11,12]. Most importantly, treatment with methadone has
been shown to reduce the risk of death as compared to no
treatment [13]. Treatment with methadone also reduces
the risk of blood-borne infections such as human
immunodeficiency virus (HIV); methadone treatment
in combination with needle exchange programs and
other harm reduction strategies has been shown to reduce
the risk of hepatitis C virus (HCV) infection [14-16].
In Western Europe, the experience of OST for the
treatment of heroin dependence is heterogeneous. In
most countries, including Spain, methadone is the
preferred drug for OST, while buprenorphine is more
common in others [17]. Approximately 90,000 patients
receive methadone treatment in Spain, and this figure has
remained constant since the early 1990’s, when OST was
focused to reduce the impact of HIV/AIDS and drug
overdose [17]. Spanish drug users were heavily impacted
by HIV infection to a point that there was a reduction
in life expectancy for the general population during
the early 1990's [18]. Despite the impact that heroin
dependence had in young adults from urban settings,
studies examining long-term disease outcomes from
MTPs in Spain are scarce [7,19].
The aim of this study was to analyze the survival of
heroin users and predictors of death in a cohort of
patients admitted to a MTP. Specifically, we aimed to
analyze sex differences in mortality, as well as temporal
changes over four calendar periods, which are characterized
by the introduction of preventive and treatment interven-
tions in metropolitan Barcelona, Spain. In doing so, our
results will inform how MTP is implemented in our area.
Methods
A longitudinal study of patients admitted to a MTP from
January 1992 to December 2010 was performed. This
MTP began in January 1992, is the only OST in the
metropolitan area that is north of Barcelona, and is
located in the CAS-Delta, Municipal Institute for
Personal Services, in Badalona. The CAS-Delta is a
primary care center for outpatient addiction treatment,
and serves an area with 400,000 inhabitants over five
municipalities, including Badalona (240,000 inhabitants)
and Santa Coloma de Gramenet (120,000 inhabitants).
Within the program, methadone is dispensed via a
primary care center, a mobile unit since 1993 and five
community pharmacies since 1999.
MTP admission criteria were as follows: patients had
to be >18 years old, and had to have an opioid dependence
according to the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) criteria. Psychosocial
interventions and harm reduction programs, such as needle
exchange, condom distribution, and supervised injection
facilities, complemented the drug treatment program.
Patients were referred to other Primary Care outpatient
facilities or hospitals in the area for additional studies, if
necessary. Additional MTP details have been published
elsewhere [20].
Socio-demographic data (age at admission, education
level, employment status, and prior imprisonment), drug
use characteristics (age at first consumption, duration
and route of administration), blood samples to test for
HIV, HBV (HBcAb+), and HCV infections, and psychiatric
history were collected at MTP admission. Information was
obtained from medical records.
The psychiatric disorders were diagnosed by specialist
at the MTP or other centers, and were divided into four
categories: 1) mood-related disorders, 2) anxiety disorders,
3) schizophrenia or other psychotic disorders, and 4)
personality disorders.
To analyze changes over time, four different time
periods were established according to the introduction
of preventive and treatment interventions in Barcelona,
Spain: 1) 1992–1996: characterized by the development of
methadone treatment and needle exchange programs. At
the same time, antiretroviral therapy (ART) emerged as a
treatment for HIV infection with monotherapy or dual
therapy of nucleotide analogues [21], 2) 1997–2001:
period that saw the widespread introduction of Highly
Active Antiretroviral Therapy (HAART), 3) 2002–2006:
period when HAART was simplified and supervised
injection facilities for IDUs were created [22-24], and
4) 2007–2010: period that represented the consolidation
of harm reduction interventions and the treatment of HIV
infection with HAART in once-daily dosing.
The present study is compliant with ethical standards
for medical research and good clinical practice principles,
in accordance with the World Medical Association’s
Declaration of Helsinki. The study was approved by
the Ethics Committee of the Hospital Universitari
Germans Trias i Pujol and written consent of patients
was obtained.
Follow-up, mortality and cause of death
Mortality and cause of death were ascertained by reviewing
clinical charts and crosschecking with the Catalonian
mortality register, as of December 31st, 2010.
Cause of death was established in accordance with the
International Classification of Diseases, Version 9 (ICD-9)
until 1998 [25], and Version 10 (ICD-10) between 1999
and 2010 [26]. Causes of death were later classified into
four categories:
1) Non-natural (including drug-related and
alcohol-related accidents, suicides, and traumas):
ICD-9: 304, 305, and E800 − E999; ICD-10:
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F10 − F19, X00 −X99, V00 −V99, W00 −W99, and
Y00 − Y36.
2) HIV/AIDS: ICD-9: 279.5 and 795.8; ICD-10:
B20 − B24 and R75.
3) Liver-related (including viral hepatitis, cirrhosis,
decompensated liver disease, and hepatocellular
carcinoma): ICD-9: 070, 155, and 570–573;
ICD-10: B15 − B19, C22, and K70 − K77.
4) Other medical causes, including non-HIV/AIDS-
related infectious diseases, and respiratory and
central nervous system disorders (codes not
specified in other categories).
Statistical analysis
Descriptive statistics were expressed as the median
(interquartile range [IQR]) for continuous variables and
as absolute frequencies and percentages for categorical
variables. We used χ-square tests, Fisher F-tests, and
Student’s t-test to detect significant differences. Patients’
entry to the cohort was defined by the first admission to
MTP; all patients were followed until December 31st 2010
or death.
Cox regression models were used to analyze the
predictors of death. Previous to the implementation
of statistical models we checked for the proportional
hazards assumption of all variables. The covariates
used for multivariate analysis were those that were
found to be statistically significant in univariate analysis.
Stepwise forward selection was used to identify predictors
establishing α = 0.05 and α = 0.1 as the inclusion and
exclusion criteria, respectively.
Mortality rates were calculated in person-years (p-y)
analysis; p-y represents the time that all persons contribute
to a longitudinal study. Rates of mortality in p-y analysis
are the quotient of the number of deaths observed during
the study period in the numerator and the sum of all the
individual follow-up times in the denominator. Temporal
changes in mortality rates were observed for four periods:
1992–1996, 1997–2001, 2002–2006, and 2007–2010.
All analyses were conducted using two-sided tests
and a significance level of 0.05. Descriptive statistics and
regression models were generated using SPSS 15.0 (SPSS,
Chicago, IL, USA). Mortality rates for the calendar years
were calculated using STATA version 8.0 (Stata Corp.,
College Station, TX, USA).
Results
The study included 1,678 patients (82.8% men). The
median age of first heroin use was 18.6 years (IQR:
16–23 years), median age at MTP admission was
30.7 years (IQR: 26–36 years) and 23.8% of patients
were non-IDUs. Forty four percent of patients were
employed, 83% had completed primary education, and
48% had prior incarceration.
Psychiatric co-morbidities were analyzed for 1,567
patients; 25% (394) were diagnosed with psychiatric
disorders, and 22% (87/394) had more than one disorder.
The most frequent diagnoses were related to mood
disorders in 45.9% (181/394), personality disorders in
34.2% (135/394), and anxiety in 17.7% (70/394). Twelve
percent (48/394) of patients were diagnosed with a psych-
otic disorder, and 8.4% (33/394) had previously attempted
suicide.
The characteristics of patients by sex are described
in Table 1. Men were more likely to have prior incarcer-
ation and women were more likely to be HIV-infected
(59.8% vs. 52.5%, p = 0.040) and to have psychiatric
co-morbidities (30.3% vs. 24.1%, p = 0.031), especially
mood disorders.
Follow-up and outcomes
Overall, the median follow-up time for the entire cohort
was 9.2 years (IQR: 4–13 years), while the total follow-up
was 15,124 p-y. At the end of follow-up, 441 (26.3%)
patients had died and 14 (3.2%) of deaths occurred within
one month of first entry to treatment. The overall mortality
rate was 2.9 per 100 p-y (95% Confidence Interval
(CI): 2.6-3.2 per 100 p-y), and the main causes of death
Table 1 Baseline characteristics of 1,390 men and 288
women admitted to a methadone treatment program in
metropolitan Barcelona, Spain, between 1992 and 2010
Men Women p value
n = 1,390 n = 288
n (%) n (%)
Age at admission (median, IQR) 31 (26–36) 30 (24–35) 0.000
Period of admission: 0.972
1992-1996 505 (36.3) 103 (35.8)
1997-2001 469 (33.7) 97 (33.7)
2002-2006 250 (18.0) 55 (19.1)
2007-2010 166 (11.9) 33 (11.5)
Social and drug use characteristics
Age at first heroin use
(median, IQR)
19 (17–22) 19 (16–24) 0.940
Injection drug use (n = 1,562) 992 (76.8) 198 (73.1) 0.184
Unemployed (n = 1,560) 703 (54.5) 164 (60.5) 0.072
Primary school attainment
(n = 1,552)
1,065 (83.1) 223 (82.3) 0.735
Prior incarceration (n = 1,480) 610 (49.8) 100 (39.4) 0.003
Co-morbidity
HIV infection (n = 1,343) 582 (52.5) 140 (59.8) 0.040
HCV infection (n = 727) 443 (73.2) 92 (75.4) 0.617
HBV infection (HBcAb+)
(n = 708)
369 (62.2) 65 (56.5) 0.250
Psychiatric disorder
(n = 1,567)
311 (24.1) 83 (30.3) 0.031
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were HIV/AIDS (40%) and non-natural (26.4%) (Table 2).
No sex differences were observed for the median
follow-up (p = 0.097), cumulative mortality (p = 0.403),
or mortality rate (p = 0.187). However, distribution of
the causes of death was significantly different between sex
(p = 0.022); HIV/AIDS-related mortality was higher in
women (53.0% vs. 37.3%) and mortality from non-natural
causes was higher in men (29.0% vs. 12.1%).
Sex-specific predictors of death
In the univariate analyses, age at admission, antecedent
of IDU, HCV, HIV and HBV infections at admission,
prior incarceration, and period of admission to MTP were
associated with mortality among men. In the multivariate
analysis, only HIV infection at admission was an independent
predictor of death (Table 3).
Among women, age at admission, antecedent of
IDU, HBV and HIV infection at admission, and prior
incarceration were associated with mortality in the
univariate analyses. In multivariate analysis, only HIV
infection at admission and prior incarceration were
predictors of death (Table 3).
Mortality trend and causes of death
Overall mortality rate decreased over time: 7.4 per 100
p-y (95% CI: 6.3-8.8 per 100 p-y) for 1992–1996, 2.7 per
100 p-y (95% CI: 2.2-3.3 per 100 p-y) for 1997–2001, 2.4
per 100 p-y (95% CI: 2.0-2.9 per 100 p-y) for 2002–2006,
and 1.9 per 100 p-y (95% CI: 1.6-2.4 per 100 p-y) for
2007–2010. A statistically significant reduction (p < 0.005)
for all pairwise relative risk of death was observed using
the first period as the reference category.
Mortality in women slightly increased during recent
periods. While the initial mortality rate decreased
from 4.4 per 100 p-y (95% CI: 2.6-7.4 per 100 p-y) in
1992–1996 to 1.8 per 100 p-y (95% CI: 0.9-3.2 per
100 p-y) in 1997–2001, it increased to 2.7 per 100 p-y (95%
CI: 1.8-3.9 per 100 p-y) in the 2002–2006 period and 2.2
per 100 p-y (95% CI: 1.4-3.5 per 100 p-y) in 2007–2010.
This increase in mortality rates was most apparent for the
HIV-infected women. Figure 1 shows the temporal trend of
mortality rates by sex and HIV status.
To analyze the recent increase in mortality of HIV-
infected women, the specific causes of death were reviewed
since January 2002. The main causes of death among the 33
HIV-positive women were AIDS-related (53.3%) and
liver-related (10%) and few of them (6.7%) died from
non-natural causes. The main causes of death among
the 116 HIV-positive men who died in the same periods
were AIDS-related (33.6%), liver-related (16.8%), and
non-natural (18.6%). Overall, there were no statistically
significant differences in the causes of death of HIV-
positive men and HIV-positive women in the last
periods (p = 0.154). However, during the last two periods
HIV-positive women showed a higher proportion of
AIDS-related deaths than HIV-positive men. (p = 0.048).
Discussion
This study provides a description of survival in opiate-
dependent men and women admitted to MTP and shows
that HIV infection is the main predictor of death in this
population. Women are more likely to be HIV-positive
than men when they are admitted to OST which is
consistent with a recent meta-analysis concluding that
female IDU are more likely to acquire HIV infection [27];
in the present study IDUs represents 75% of cases.
On the other hand, women from this study were more
likely to receive a diagnostic of psychiatric disorder than
men which is also consistent with a previous study [22].
Psychiatric comorbidity in this series is high; up to 25%
of patients had a mental health disorder before or upon
admission to the MTP. However, prevalence of psychiatric
disorders in patients with substance abuse is heterogeneous
probably because differences in the diagnostic methods or
due to the difficulty in obtaining psychiatric diagnoses for
drug users [28,29].
A systematic review of longitudinal studies found that
the mortality of heroin-dependent patients varies across
countries. Specifically, the pooled crude death rate for
all cause mortality was 2.22 × 100 p-y in Western
Europe [13]. The mortality of patients in MTP in the
present study is even higher, probably due to the impact
of HIV/AIDS on survival. Regarding other factors that
may influence survival of patients admitted to an OST, we
cannot exclude the role that methadone dosage changes
and treatment interruptions may have on mortality, as this
information that was not available.
In this study, deaths due to non-natural causes, including
drug overdose, was significantly higher in men than in
women. This finding is consistent with mortality data from
Table 2 Outcomes of interest at the end of follow-up
(December 31th, 2010) in 1,678 opiate users admitted to
a methadone treatment program between 1992-2010
Men Women p value
n = 1,390 n = 298
Total follow-up length (p-y) 12,356 2,768
Median follow-up (IQR), years 9.1 (3.8-12.8) 9.6 (4.9-13.8) 0.097
Deaths, n (%) 371 (26.7) 70 (24.3) 0.403
Mortality Rate, per 100 p-y
(95% CI)
3.0 (2.7-3.3) 2.5 (2.0-3.2) 0.187
Causes of death (n = 425) 0.022
HIV/AIDS 134 (37.3) 35 (53.0)
Non-natural 104 (29.0) 8 (12.1)
Liver 38 (10.6) 8 (12.1)
Other 83 (23.1) 15 (22.7)
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European heroin users for whom the male:female ratio for
drug overdose deaths is 4:1 [1]. However, a recent study on
patients in a MTP demonstrated that the excess mortality
due to non-natural causes is higher in women when the
standardized mortality ratio is considered [30].
As it has been alredy mentioned, HIV/AIDS was a
strong predictor of death, irrespective of gender.
These results are consistent with others that have also
shown a significant impact of HIV/AIDS on the survival
of patients in a MTPs [7,31-33]. Furthermore, HIV
infection in patients on OST is a surrogate of injec-
tion drug use; in fact, non-IDUs have a fivefold lower
risk of HIV infection than IDUs, as shown in previous
studies [34,35]. In addition, prior incarceration was a risk
factor of death in women herein. Imprisonment before
being admitted to an OST program may be an indicator
Table 3 Cox regression models for predictors of death in 1,390 men and 288 women admitted to a methadone
treatment program in metropolitan Barcelona, Spain, between 1992 and 2010
Men Women
Univariate Multivariate1 Univariate Multivariate2
HR CI 95% HR CI 95% HR CI 95% HR CI 95%
Age at admission 1.03 1.02-1.05 1.04 1.00-1.08
Period of admission
1992-1996 2.33 1.18-4.59 1.24 0.28-5.44
1997-2001 1.31 0.66-2.62 0.90 0.20-4.02
2002-2006 0.96 0.45-2.01 0.86 0.17-4.21
2007-2010 1 1
Social and drug use characteristics
Age at first heroin use 1.01 0.99-1.03 1.02 0.97-1.07
Injection drug use 2.87 1.97-4.18 7.38 2.32-23.52
Unemployed 1.18 0.95-1.46 0.98 0.59-1.62
Primary school attainment 1.27 0.97-1.65 0.79 0.40-1.54
Prior incarceration 1.50 1.21-1.86 2.53 1.50-4.26 3.07 1.33-7.07
Co-morbidity
HIV infection 4.01 3.09-5.21 3.5 2.09-5.74 5.46 2.49-11.99 3.20 1.18-8.70
HCV infection 2.37 1.44-3.90 3.42 0.80-14.61
HBV infection (HBcAb+) 1.45 1.02-2.05 3.25 1.23-8.58
Psychiatric disorder 1.06 0.83-1.36 0.70 0.39-1.26
Multivariate Cox regression with stepwise forward selection method. Statistically significant predictors are in bold (p < 0.05).
1Multivariate analysis for men included age at admission, injection drug use, prior incarceration, HIV infection, HCV infection and HBV infection.
2Multivariate analysis for women included age at admission, injection drug use, prior incarceration, HIV infection and HBV infection.
Figure 1 Sex-specific mortality rates according to four calendar periods and HIV status among patients admitted to a methadone
treatment program in metropolitan Barcelona, Spain, 1992–2010.
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of low socioeconomic status and of the severity of
drug dependence [36].
This study shows that overall mortality decreased
over the two decades analyzed. Significant reductions
in the mortality of heroin-dependent patients has
been reported in Spain since 1995 [37]; the lower mortal-
ity was attributed to the progressive introduction of harm
reduction interventions and the dissemination of OST
programs.
Another finding of this study is the decline in the
number of first time admissions to methadone treat-
ment. Assuming that access to substitution treatment
did not change over the study period, there are several
potential explanations for the observed decline. First, a
lower number of admissions may indicate fewer heroin
users in the community; second, the emergence of other
heroin substitutes, such as buprenorphine, may re-
duce the number of patients admitted to the MTP;
and third, the irruption of supervised injection facil-
ities in Spain may have produced a shift in attitudes
of IDUs, favoring the use of injected heroin in a safe
facility. Data from other health indicators support
the hypothesis that the decrease in MTP patients
may be associated with fewer heroin users in the
Barcelona area [38].
This study has several limitations that should be
mentioned. First, the number of available clinical and
epidemiological variables is limited; thus, it is difficult
to determine the impact of additional co-morbidities
on survival. However, HIV/AIDS and HCV infections,
two diseases with a great impact on survival of patients
with a history of IDU, were included as covariates in our
analysis [1]. Second, the frequency of poly-drug use while
on methadone was not known; it is likely that concurrent
use of cocaine and/or alcohol might be associated
with an increased risk of death in this population
[39]. Third, this study did not analyze neither changes
over time regarding methadone dose and treatment
interruptions nor changes in HIV and HCV serostatus; in
this sense, methadone dose, treatment interruptions and
blood-borne infections have been associated with disease
outcomes [33,40].
Conclusion
In conclusion, this study aimed to analyze disease
outcomes in a large cohort of patients admitted to an
MTP during 19 years of recruitment and follow-up.
The MTP main characteristics have not changed since
the program’s inception in 1992 and it is the only
MTP in an urban area with a population of 400,000.
Adapting treatment delivery to patients’ life conditions
and improving the coordination of different health care
levels is essential to improve survival of drug-dependent
patients treated with methadone.
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